Baird initiated coverage of Vaxxinity with an Outperform rating and $7 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VAXX:
- Vaxxinity to Present at Upcoming Investor Conferences in September
- Vaxxinity announces publication of Phase 2 trial of UB-311
- Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
- Vaxxinity reports Q2 EPS (11c) vs (14c) last year
- Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update